High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: A prognostic model for treatment outcomes

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 2, 1997, Pages 98-106

  Wheeler, Catherine ^a   Eickhoff, Christine ^b   Elias, Anthony ^b   Ibrahim, Joseph ^b   Ayash, Lois ^b   McCauley, Mary ^b   Mauch, Peter ^b   Schwartz, Gary ^b   Eder, Joseph Paul ^b   Mazanet, Rosemary ^b   Ferrara, James ^b   Rimm, Ilonna J ^b   Guinan, Eva ^b   Bierer, Barbara ^b   Gilliland, Gary ^b   Churchill, W Hallowell ^b   Ault, Kenneth ^b   Parsons, Susan ^b   Antman, Karen ^b   Schnipper, Lawell ^b   Tepler, Isidore ^b   Gaynes, Lisa ^b   Frei III, Emil ^b   Kadin, Marshall ^b   Antin, Joseph ^b   more..

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Bone marrow transplantation; High dose therapy; Hodgkin's disease; Prognostic factors

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0031158343     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVTD. N Eng J Med 327:1478, 1992.
2. Longo DL, Duffely PL, Young RC, Hubbard SM, Ibde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr.: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210, 1992.
3. Viviani S, Santoro A, Negretti E, Bonfante V, Valagussa P, Bonadonna G: Salvage chemotherapy in Hodgkin's disease. Annals Oncol 1:123, 1990.
4. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE, Bensinger WI, Martin PJ, Storb R, Sullivan KM, Hansen JA, Thomas ED: Allogeneic, syngeneic and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11:2342, 1993.
5. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center eight-year study of 155 patients. Blood 81:1137, 1993.
6. Kessinger A, Bierman PJ, Vose JM, Armitage JO: High-dose cyclophosphamide, carmustine and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 77:2322, 1991.
7. Reece DE, Connors JM, Spinelli JJ, Barnett M, Fairey RN, Klingemann HG, Nanter SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83:1193, 1994.
8. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, Valagussa P, Bonadonna G: Prolonged disease-free survival after high-dose sequential chemoradiotherapy and haemopoetic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 2:645, 1991.
9. Reece DE, Barnett MJ, Connors JM, Fairey RN, Greer JP, Herzig GP, Herzig RH, Klingemann HG, O'Reilly SE, Shepherd JD, Spinelli JJ, Voss NJ, Wolff SN, Phillips GL: Intensive chemotherapy with cyclophosphamide, carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 9:1871, 1991.
10. Jones RJ, Piantadosi S, Mann RB, Ambinder RF, Seifter EJ: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 8:527, 1990.
11. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughn WP, Kessinger A, Horowitz LJ, Hagemeister FB, McLaughlin P, Cabanillas F, Spitzer G: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7:179, 1989.
12. Armitage JO, Bierman PJ, Vose JM, Anderson JR, Weisenburger DD, Kessinger A, Ree EC, Vaughn WP, Coccia PF, Purtilo DT: Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 91:605, 1991.
13. Bierman P, Bagin RG, Jagannath S, Vose JM, Spitzer C, Kessinger A, Dicke K, Armitage J: High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term followup in 128 patients. Annals Oncol 4:767, 1993.
14. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE, Eder JP: Cyclophosphamide, carmustine and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose finding study. J Clin Oncol 8:648, 1990.
15. Bierman P, Anderson JR, Freeman MB, Vose JM, Kessinger A, Bishop MR, Armitage JO: High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Annals Oncol 7:151, 1996.
16. Horning, SJ, Nelson CJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801, 1997.
17. Bierman PJ, Vose JM, Armitage JO: Autologous transplantation for Hodgkin's disease: Coming of age? Blood 83:1161, 1994.
18. Desch CE, Lasala MR, Smith TJ, Hillner BE: The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 10:200, 1992.
19. Philip T, Gulielmi C, Hagenbeek A, Somers R, Van der Leleie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapse of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540, 1995.
20. Long GD, Negrin RS, Hoyle CF, Kusneirz-Glaz CR, Schriber JR, Blume KG, Chao NJ: Multiple cycles of high-dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 76:860, 1995.
21. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Durkop H, Aversa F, Corneli P, Pizzolo G, Barbietola G, Sabattini E, Pileri S, Martelli MF, Stirpe F: Response of refractory Hodgkin's disease to monocolonal anti-CD30 immunotoxin. Lancet 339:1195, 1992.
22. Schenkein D, Dixon P, Desforges JF, Berkman E, Erban JK, Ascensao JL, Miller KB: Phase I/II study of cyclophosphamide, carboplatin and etoposide and autologous hematopoetic stem cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease. J Clin Oncol 12:2423, 1994.
23. Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A: Immunotherapy with interleukin 2 with or without lymphokine-activated cells after autologous bone marrow transplantation for malignant lymphoma: A feasibility trial. Bone Marrow Transplantation 16:283, 1995.
24. Herpst JM, Klein JL, Leichner PK, Quadri SM, Vriesendorp HM: Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol 13:2394, 1995.
25. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814, 1997.